Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Apr;10(2):77-90.
doi: 10.2174/156652310791111001.

Building better chimeric antigen receptors for adoptive T cell therapy

John S Bridgeman  1 , Robert E Hawkins, Andreas A Hombach, Hinrich Abken, David E Gilham
Affiliations
Review

Building better chimeric antigen receptors for adoptive T cell therapy

John S Bridgeman et al. Curr Gene Ther. 2010 Apr.

Abstract

The last few years have seen the transfer of two decades of research into Chimeric Antigen Receptors (CARs) into clinical trials. Despite this extensive research, there is still a great deal of debate into the optimal design strategy for these, primarily, anti-cancer entities. The archetypal CAR consists of a single-chain antibody fragment, specific to a tumour-associated antigen, fused to a component of the T-cell receptor complex (typically CD3zeta) which on antigen binding primes the engrafted T-cell for anti-tumour activity. The modular nature of these artificial receptors has enabled researchers to modify aspects of their structure, including the extracellular spacer, transmembrane and cytoplasmic domain, to achieve laboratory defined optimal activity. Despite this there is no consensus on the optimal structure, a problem exacerbated by conflicting results using identical receptors. In this review, we provide a structural overview of CAR development and highlight areas that require further refinement. We also attempt to identify possible reasons for conflicting results in the hope that this information will inspire future rational design strategies for optimal tumour targeting using CARs.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Challenges and future perspectives of T cell immunotherapy in cancer.
    de Aquino MT, Malhotra A, Mishra MK, Shanker A. de Aquino MT, et al. Immunol Lett. 2015 Aug;166(2):117-33. doi: 10.1016/j.imlet.2015.05.018. Epub 2015 Jun 19. Immunol Lett. 2015. PMID: 26096822 Free PMC article. Review.
  • Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
    Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG. Lipowska-Bhalla G, et al. Cancer Immunol Immunother. 2012 Jul;61(7):953-62. doi: 10.1007/s00262-012-1254-0. Epub 2012 Apr 22. Cancer Immunol Immunother. 2012. PMID: 22527245 Free PMC article. Review.
  • Advances in cancer immunotherapy.
    Snook AE, Waldman SA. Snook AE, et al. Discov Med. 2013 Feb;15(81):120-5. Discov Med. 2013. PMID: 23449114 Free PMC article. Review.
  • CARs on track in the clinic.
    Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M, Heslop HE. Kohn DB, et al. Mol Ther. 2011 Mar;19(3):432-8. doi: 10.1038/mt.2011.1. Mol Ther. 2011. PMID: 21358705 Free PMC article. No abstract available.
  • Role of T cells in cancer immunotherapy: Opportunities and challenges.
    Ahmed H, Mahmud AR, Siddiquee MF, Shahriar A, Biswas P, Shimul MEK, Ahmed SZ, Ema TI, Rahman N, Khan MA, Mizan MFR, Emran TB. Ahmed H, et al. Cancer Pathog Ther. 2022 Dec 20;1(2):116-126. doi: 10.1016/j.cpt.2022.12.002. eCollection 2023 Apr. Cancer Pathog Ther. 2022. PMID: 38328405 Free PMC article. Review.
See all "Cited by" articles

Publication types

MeSH terms

Substances

LinkOut - more resources